$MTVA SEC Filings

Filed On	Filing
28 Oct 2026	8-K: Regulation FD Disclosure CAMBRIDGE, Mass., October 28, 2026 – MetaVia Inc. (Nasdaq: MTVA), a clinical-stage biotechnology company focused on transforming cardiometabolic diseases, today announced that an abstract highlighting data from the Phase 1 clinical trial...
13 Oct 2026	Form 4: Browne Sarah Kaplan, Chief Medical Officer Received 53,000 shares as a grant or award
13 Oct 2026	Form 3: Browne Sarah Kaplan, Chief Medical Officer No securities owned
13 Oct 2026	8-K: Regulation FD Disclosure; Other Events Brings Extensive Experience Leading Liver and Metabolic Disease Drug Development Programs, Including MASH, and Successfully Advancing Therapies Through Phase 2 and Into Phase 3 Development
09 Sep 2026	8-K: Regulation FD Disclosure; Other Events Tissue Distribution Study Shows Highest Exposure in Adipose Tissue and Prolonged Retention Consistent with Once-Weekly Dosing Findings Provide Mechanistic Support for the Differentiated Profile of DA-1726
06 Aug 2026	10-Q
06 Aug 2026	8-K: Results of Operations and Financial Condition; Regulation FD Disclosure
09 Jul 2026	8-K: Regulation FD Disclosure; Other Events
02 Jul 2026	424B5
02 Jul 2026	8-K: Other Events
08 Jun 2026	Form 4: Tursi James Patrick, Director Received 17,186 shares as a grant or award
08 Jun 2026	Form 4: Strickland D Gordon, Director Received 17,186 shares as a grant or award
08 Jun 2026	Form 4: Salsbury Michael, Director Received 17,186 shares as a grant or award
08 Jun 2026	Form 4: Groves Jason L, Director Received 17,186 shares as a grant or award
08 Jun 2026	Form 4: Koven Andrew I, Director Received 17,186 shares as a grant or award
08 Jun 2026	Form 4: Glickman Mark A, Director Received 17,186 shares as a grant or award
08 Jun 2026	FORM S-8
08 Jun 2026	8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders
08 Jun 2026	8-K: Regulation FD Disclosure; Other Events
27 May 2026	8-K: Regulation FD Disclosure

Comments